Iconovo appoints Henrik Damkjær Simonsen as Chief Financial Officer
Iconovo AB (publ), that develops complete inhalation products for a global market, today announces that Henrik Damkjær Simonsen has been appointed Chief Financial Officer, as of April 1, 2023. He succeeds Peter Åkerlund who has been acting CFO since November 16 of this year.
Iconovo’s ICOone® inhaler platform receives new patent approval in the US
Iconovo AB (publ), that develops inhalation products for a global market, today announced that the United States Patent and Trademark Office (USPTO) intends to approve an additional patent for ICOone® – an innovative inhaler platform that enables convenient and cost-effective administration of vaccines and biologics. Iconovo is already pursuing several development projects based on ICOone®, including one with financial support from the Bill & Melinda Gates Foundation.
Nomination Committee appointed at Iconovo
At the Annual General Meeting of 17 May 2022, it was resolved that Iconovo shall have a Nomination Committee consisting of four members representing the four largest shareholders as of 30 September each year.
Abbreviated interim report 1 January – 30 September
ICOone development supported by Bill & Melinda Gates Foundation
Iconovo’s unique single dose inhaler ICOone® Nasal received high marks in user study
Iconovo AB (publ), that develops inhalation products for a global market, has conducted a user study to assess the handling of its ICOone® Nasal inhaler. The aim is to simplify the usage of ICOone® Nasal so that users can operate it correctly without detailed instructions.
Iconovo receives USD 883,800 grant from recognized international foundation to develop inhaled therapy with ICOone Nasal for the next pandemic
Iconovo, that develops inhalation products for a global market, today announces that it has received a grant of USD 883,800 from the Bill & Melinda Gates Foundation. The grant work plan is focused on the development of a low-cost device that can provide delivery of medical compounds to the full (upper and lower) respiratory tract and will be performed in the period August 2022 – June 2023. The purpose is to establish a fast track for inhaled therapies that will facilitate improved global healthcare, primarily in low- and middle-income countries, in the event of a new virus pandemic.
Abbreviated interim report 1 January – 30 June 2022
High customer activity level and preparation for clinical trials
Iconovo receives approval of additional patent for ICOres® in the EU
Iconovo AB (publ), that develops complete inhalation products for a global market, today announced that the European Patent Office (EPO) has provided a Notice of Allowance regarding an additional patent application for the inhaler platform ICOres. ICOres is currently being used in several of Iconovo’s customer projects and this additional patent will bring a longer and improved protection period for customers launching in the future.
First patent granted in Japan for Iconovo’s ICOone
Iconovo AB (publ), that develops complete inhalation products for a global market, today announces that the Japanese patent authority JPO has submitted a Notice of Allowance regarding Iconovo's patent application for the inhaler platform ICOone. The patent describes the single-dose inhaler which is currently part of three innovative partner projects including the administration of oxytocin and covid-19 vaccine. Iconovo already has a well-established patent portfolio for ICOone in Sweden, Europe (EPO), USA, China, and India.
Iconovo updates its long-term financial targets – expects strong revenue growth with a high margin
Iconovo AB (publ), that develops complete inhalation products for a global market, today announces its five-year targets for the company. The company expects to reach sales of SEK 250 million in 2027. The target for the operating profit in the same year is SEK 125 million, resulting in an operating margin of 50 percent. The company expects about one third of the revenue stream to come from Iconovo's own pharmaceutical sales in the Nordic region through its subsidiary Iconovo Pharma. Iconovo's future prospects and financial targets was described in more detail at a Capital Markets Day in Swedish and the presentations will soon be available on the company´s website.